Solution Group's Convidecia vaccine gets WHO's emergency use approval

By Azanis Shahila Aman - May 20, 2022 @ 1:58am

Solution Group Bhd's (SGB) subsidiary, Solution Biologics Sdn Bhd (SOLBIO), has received the World Health Organization's (WHO) Emergency Use Listing (EUL) for its Covid-19 vaccine, Convidecia.(Photo by JORGE GUERRERO / AFP)

KUALA LUMPUR: Solution Group Bhd's (SGB) subsidiary, Solution Biologics Sdn Bhd (SOLBIO), has received the World Health Organization's (WHO) Emergency Use Listing (EUL) for its Covid-19 vaccine, Convidecia.

SOLBIO is the ASEAN manufacturing partner of CanSino Biologics Inc (CanSinoBIO).

CanSinoBIO chairman and chief executive officer Xuefeng Yu said this EUL would significantly contribute to the expansion of vaccine access to underserved populations around the globe.

Yu said it would also represent a significant milestone for CanSinoBIO and further demonstrate its efforts in the pandemic fight.

"We are actively working with public and private organizations to grant access to Convidecia.

"Looking ahead, we will continue to innovate and develop new products to diversify our vaccine portfolio further, including inhaled and mRNA vaccines," he said in a statement.

Convidecia is CanSinoBIO's Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector) for individuals aged 18 years and above.

In addition to shortening the vaccination cycle by leveraging the advantages of its single-dose regimen, Convidecia can be stably transported and stored between 2°C and 8°C.

This will make it more accessible to developing countries with inadequate storage facilities and medical resources.

CanSinoBIO's Convidecia has received approval in more than 10 markets, namely China, Mexico, Ecuador, Chile, Argentina, Hungary, Kyrgyzstan, Pakistan, United Arab Emirates, Indonesia, and Malaysia.

The company also established local partnerships for distribution in various countries, including setting up fill-and-finish facilities in Mexico, Pakistan, and Malaysia, allowing its Covid-19 vaccine access to more people in developing markets.

So far, Convidecia has been approved as a heterologous booster vaccine in China, Argentina, Malaysia and Indonesia.

It is also the first and only adenovirus-vectored vaccine to be included in the heterologous vaccination program in China.